Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

AC Immune (ACIU) Equity Average (2016 - 2025)

AC Immune has reported Equity Average over the past 9 years, most recently at $67.1 million for Q4 2025.

  • Quarterly Equity Average fell 51.79% to $67.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.1 million through Dec 2025, down 51.79% year-over-year, with the annual reading at $92.2 million for FY2025, 40.4% down from the prior year.
  • Equity Average was $67.1 million for Q4 2025 at AC Immune, down from $84.2 million in the prior quarter.
  • Over five years, Equity Average peaked at $218.5 billion in Q2 2021 and troughed at $67.1 million in Q4 2025.
  • The 5-year median for Equity Average is $166.0 million (2023), against an average of $31.7 billion.
  • Year-over-year, Equity Average surged 81589.78% in 2021 and then plummeted 99.9% in 2022.
  • A 5-year view of Equity Average shows it stood at $97.7 billion in 2021, then plummeted by 99.81% to $186.1 million in 2022, then fell by 13.12% to $161.7 million in 2023, then fell by 13.91% to $139.2 million in 2024, then plummeted by 51.79% to $67.1 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Equity Average are $67.1 million (Q4 2025), $84.2 million (Q3 2025), and $97.9 million (Q2 2025).